Janux Therapeutics, Inc. (NASDAQ:JANX) Receives $89.90 Average PT from Analysts

Janux Therapeutics, Inc. (NASDAQ:JANX) has earned an average rating of “Buy” from the twelve analysts that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, ten have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $89.90.

JANX has been the subject of several research reports. UBS Group began coverage on shares of Janux Therapeutics in a research report on Thursday, October 24th. They issued a “buy” rating and a $69.00 price objective for the company. BTIG Research lifted their target price on Janux Therapeutics from $82.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, December 3rd. Leerink Partners increased their price target on Janux Therapeutics from $79.00 to $91.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 3rd. Leerink Partnrs upgraded Janux Therapeutics to a “strong-buy” rating in a report on Friday, November 22nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $200.00 price objective on shares of Janux Therapeutics in a research note on Wednesday, December 11th.

Janux Therapeutics Price Performance

Shares of JANX opened at $56.14 on Friday. Janux Therapeutics has a 1 year low of $7.79 and a 1 year high of $71.71. The business’s 50 day simple moving average is $54.24 and its 200-day simple moving average is $47.30. The stock has a market capitalization of $2.95 billion, a price-to-earnings ratio of -47.98 and a beta of 3.29.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.18). Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The firm had revenue of $0.44 million for the quarter, compared to analysts’ expectations of $1.50 million. The firm’s revenue for the quarter was down 82.6% compared to the same quarter last year. On average, sell-side analysts expect that Janux Therapeutics will post -1.35 earnings per share for the current year.

Insider Buying and Selling at Janux Therapeutics

In other Janux Therapeutics news, major shareholder Ventures Xi L.P. Avalon sold 49,231 shares of the company’s stock in a transaction on Friday, September 27th. The shares were sold at an average price of $46.45, for a total transaction of $2,286,779.95. Following the completion of the transaction, the insider now directly owns 6,926 shares in the company, valued at approximately $321,712.70. This represents a 87.67 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Andrew Hollman Meyer sold 50,000 shares of Janux Therapeutics stock in a transaction that occurred on Friday, September 27th. The stock was sold at an average price of $45.96, for a total value of $2,298,000.00. Following the completion of the sale, the insider now directly owns 67,592 shares in the company, valued at $3,106,528.32. This represents a 42.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 192,032 shares of company stock valued at $9,512,515. Corporate insiders own 29.40% of the company’s stock.

Hedge Funds Weigh In On Janux Therapeutics

A number of institutional investors have recently bought and sold shares of JANX. FMR LLC grew its position in Janux Therapeutics by 0.6% in the third quarter. FMR LLC now owns 7,824,675 shares of the company’s stock worth $355,475,000 after acquiring an additional 47,075 shares during the period. Janus Henderson Group PLC lifted its stake in Janux Therapeutics by 40.0% during the 3rd quarter. Janus Henderson Group PLC now owns 2,523,406 shares of the company’s stock worth $114,587,000 after acquiring an additional 721,563 shares in the last quarter. Logos Global Management LP boosted its holdings in Janux Therapeutics by 400.0% during the 2nd quarter. Logos Global Management LP now owns 750,000 shares of the company’s stock valued at $31,418,000 after acquiring an additional 600,000 shares during the period. Geode Capital Management LLC grew its position in Janux Therapeutics by 6.2% in the 3rd quarter. Geode Capital Management LLC now owns 662,594 shares of the company’s stock valued at $30,107,000 after acquiring an additional 38,490 shares in the last quarter. Finally, Point72 Asset Management L.P. increased its stake in Janux Therapeutics by 190.2% during the third quarter. Point72 Asset Management L.P. now owns 395,875 shares of the company’s stock worth $17,985,000 after purchasing an additional 259,445 shares during the period. 75.39% of the stock is owned by hedge funds and other institutional investors.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.